Literature DB >> 9649248

Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of upper tract urothelial tumors.

R Waidelich1, A Hofstetter, H Stepp, R Baumgartner, E Weninger, M Kriegmair.   

Abstract

PURPOSE: Photodynamic therapy is effective in the treatment of superficial urothelial cancer of the bladder. We report our experience with photodynamic therapy for the treatment of upper urinary tract transitional cell carcinoma.
MATERIALS AND METHODS: Photodynamic therapy after oral administration of 5-aminolevulinic acid was performed in 4 patients with widespread superficial papillary tumors of the upper urinary tract.
RESULTS: Complete remission occurred in 2 patients who remained free of local recurrence at 7 and 17 months of followup. In the other 2 patients residual tiny papillary tumors were found in the distal ureter after photodynamic therapy. These tumors were coagulated with neodymium:YAG laser irradiation. Both patients are disease-free at 24-month followup.
CONCLUSIONS: Photodynamic therapy with 5-aminolevulinic acid is a minimally invasive approach for organ preserving treatment of multifocal superficial transitional cell carcinoma of the upper urinary tract.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649248     DOI: 10.1016/s0022-5347(01)63932-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

Review 1.  Photodynamic therapy: a review.

Authors:  J S McCaughan
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

Review 2.  The Dark Side: Photosensitizer Prodrugs.

Authors:  Sara Sansaloni-Pastor; Jordan Bouilloux; Norbert Lange
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-04

3.  Derivatives of 5-aminolevulinic Acid for photodynamic therapy.

Authors:  Ryan F Donnelly; Paul A McCarron; A David Woolfson
Journal:  Perspect Medicin Chem       Date:  2007-12-11

4.  Accuracy of photodynamic diagnosis in the detection and follow-up of patients with upper urinary tract lesions: Initial 3-year experience.

Authors:  Omar M Aboumarzouk; Sarfraz Ahmad; Harry Moseley; Slawomir G Kata
Journal:  Arab J Urol       Date:  2012-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.